chufangao/CTO huggingface dataset:
Clinical trial NCT00946712: S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Official title: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Sponsor: SWOG Cancer Research Network (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: terminated at pre-planned futility analysis
Enrollment: 1333.0 (ACTUAL)
Number of arms: 2.0
Start date: 2009-07-15
Primary completion date: 2017-08-31
Completion date: 2022-02-08
Baseline population: Only eligible patients are included in the analysis.
Clinical trial NCT02762266: Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
Official title: International Randomized Study of Transarterial Chemoembolization (TACE) Versus Stereotactic Body Radiotherapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma After Initial TACE
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Business decision - funding
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-27
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Baseline population: Participants who received treatment
Limitations and caveats: This study did not enroll the planned number of participants and did not meet the protocol-prespecified threshold for statistical significance.
Plan to share individual participant data: NO
Clinical trial NCT05447364: Efficacy of Different Doses of Pregabalin as a Multimodal Analgesic Agent in Postoperative Pain Control After Total Knee Arthroplasty
Official title: Efficacy of Different Doses of Pregabalin as a Multimodal Analgesic Agent in Postoperative Pain Control After Total Knee Arthroplasty - A Randomized Controlled Trial
Sponsor: Thammasat University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 82.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-01
Primary completion date: 2023-09-01
Completion date: 2024-03-01
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)
IPD time frame: Beginning 3 months and ending 5 years following article publication.
IPD access criteria: * Researchers who provide a methodologically sound proposal.~* To achieve aims in the approved proposal.~* Proposals should be directed to thesekku@gmail.com.~* To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT02344407: Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Official title: Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 1500.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-01-20
Primary completion date: 2016-06-01
Completion date: 2020-11-01
Clinical trial NCT03504774: Food Allergen OIT for Shrimp and Cashew
Official title: T Cell Reagent Research for Monitoring T Cells in Food Allergy (MOTIF) Phase 2 Study Using Food Allergen Oral Immunotherapy for Shrimp or Cashew Allergies
Acronym: MOTIF
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study discontinued due to slow enrollment during COVID-19 pandemic
Enrollment: 58.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-09
Primary completion date: 2023-01-13
Completion date: 2023-03-03
Limitations and caveats: Due to the COVID-19 pandemic, this study did not enroll the planned number of participants and did not meet the protocol-specified threshold for statistical significance.
Plan to share individual participant data: NO
Clinical trial NCT04220008: Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
Official title: Vorinostat With Gemcitabine/Clofarabine/Busulfan for Allogeneic Transplantation for Aggressive Lymphomas
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No Participants Enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-10-29
Primary completion date: 2021-10-29
Completion date: 2021-10-29
Clinical trial NCT04382053: Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia
Official title: Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 143.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-27
Primary completion date: 2020-12-10
Completion date: 2020-12-24
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT04623996: A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS
Official title: A Phase 1/2, Open-Label Clinical Study To Evaluate Safety And Efficacy Of TP-0184 To Treat Anemia When Administered To Adult Patients With IPSS-R Low Or Intermediate Risk Myelodysplastic Syndromes
Sponsor: Sumitomo Pharma America, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Due to limitations imposed by the COVID pandemic and the competitive landscape for myelodysplastic syndrome, this study was unable to enroll a sufficient patient population.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-28
Primary completion date: 2021-04-27
Completion date: 2021-04-27
Baseline population: The company decided to terminate further development of the TP-0184 program. No patients were enrolled into phase 2.
Plan to share individual participant data: NO
Clinical trial NCT06461949: Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
Official title: A Randomized, 52-Week Treatment Double-Blind, Placebo-Controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Closed by sponsor, lack of enrollment.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-07-17
Primary completion date: 2024-07-17
Completion date: 2024-07-17
Plan to share individual participant data: YES
IPD sharing description: .Research Data for Statistical Analysis and Scientific Reporting will be shared. All participant data will be de-identified. Participants will be identified only by a unique study identification number.
IPD time frame: Post study completion and as determined by NIDCD staff.
Clinical trial NCT03430687: Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
Official title: A Phase I Study of Intravesical Talimogene Laherparepvec for Non-Muscle Invasive Transitional Cell Carcinoma
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Investigators prefer to pursue other studies
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-01
Primary completion date: 2019-12-31
Completion date: 2020-12-31
Clinical trial NCT03951961: Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Official title: Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Sponsor: University of Jena (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient Recruitment
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-03-20
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Plan to share individual participant data: NO
Clinical trial NCT03149107: Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients
Official title: Multimodal Prevention of First Psychotic Episode - a 2x2-Factorial Randomized Trial Investigating the Efficacy of Acetylcysteine and Integrated Preventive Psychological Intervention in Subjects Clinically at High Risk for Psychosis
Acronym: ESPRIT-B1
Sponsor: University Hospital, Bonn (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Recruitment not sufficient
Enrollment: 48.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-09-01
Primary completion date: 2021-01-31
Completion date: 2021-01-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02772965: Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Pragmatic Clinical Trial To Evaluate The Effectiveness Of Low Dose Oral Methotrexate In Patients With Pediatric Crohn's Disease Initiating Anti-TNF Therapy
Acronym: COMBINE
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 306.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-10-31
Primary completion date: 2022-04-07
Completion date: 2022-04-07
Baseline population: Modified Intent to Treat population presented.
Plan to share individual participant data: NO
Clinical trial NCT03088293: Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)
Official title: A Multicenter Randomized Open-label Trial Comparing the Efficacy and Safety of Infliximab Versus Cyclophosphamide in Subjects With Idiopathic Refractory Scleritis
Acronym: CIRIS
Sponsor: Hospices Civils de Lyon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: recruiting difficulties
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-11
Primary completion date: 2023-10-31
Completion date: 2024-07-31
Clinical trial NCT02438995: Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Official title: Phase I Trial of Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-05-31
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Clinical trial NCT01543490: Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects
Official title: A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis
Acronym: ISV-305
Sponsor: Sun Pharmaceutical Industries Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 558.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-30
Primary completion date: 2020-02-04
Completion date: 2020-02-04
Baseline population: Demographics were summarized for the Intent-to-treat (ITT) Population, which included all randomized participants regardless of whether post-baseline measures were collected or study treatment was received.
Clinical trial NCT04940871: Study to Assess the Efficacy and Safety of Favipiravir-HU
Official title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Favipiravir-HU Compared to Placebo as add-on Therapy to Standard of Care in Asymptomatic to Mild Severity COVID-19 Patients
Sponsor: University of Pecs (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Only one patient was enrolled, who who later withdrew the consent. They decided not to contunie the study.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-25
Primary completion date: 2021-11-29
Completion date: 2021-11-29
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04420455: The Effects of Enoximone in Acute Exacerbation COPD
Official title: The Effects of Enoximone in Acute Exacerbation COPD
Sponsor: Rijnstate Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: A limited number of inclusions due to the Covid-pandemic
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-12
Primary completion date: 2021-12-21
Completion date: 2021-12-21
Plan to share individual participant data: YES
IPD time frame: after publication
IPD access criteria: upon reasonable request, available by the researchers
Clinical trial NCT03879655: Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
Official title: A Phase 2B/3 Open-label Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 Disease Previously Treated Under Protocol VTS301
Sponsor: Mandos LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Terminated by previous Sponsor decision
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-02
Primary completion date: 2021-10-18
Completion date: 2021-10-18
Baseline population: All enrolled participants
Limitations and caveats: Study was terminated by the Sponsor and only 2 participants were enrolled in the study.
Plan to share individual participant data: NO
Clinical trial NCT03589105: A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
Official title: An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis
Acronym: PRO-MSACTIVE
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 423.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-06
Primary completion date: 2021-02-15
Completion date: 2021-02-15
Clinical trial NCT04162028: Pre-hospital Nebulized Ketamine for Pain
Official title: Pre-hospital Utilization of Nebulized Sub-dissociative Dose Ketamine for Managing Acute Traumatic Extremity Pain: a Prospective Observational Study
Sponsor: Maimonides Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Investigators not interested any more in the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-15
Primary completion date: 2021-07-28
Completion date: 2021-07-28
Clinical trial NCT05127421: Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
Official title: A Phase 2, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 77.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-10
Primary completion date: 2023-08-03
Completion date: 2023-09-29
Plan to share individual participant data: YES
IPD sharing description: Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
IPD access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Clinical trial NCT04606576: Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
Official title: A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With T2DM With Inadequate Glycemic Control on 1, 2 or 3 Oral Glucose-lowering Agents.
Sponsor: Oramed, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: ORA-D-013-1 was terminated based on the primary results analyzed at the end of the treatment, week 26.
Enrollment: 710.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-12-15
Primary completion date: 2023-01-13
Completion date: 2023-01-13
Plan to share individual participant data: NO
Clinical trial NCT02902133: Acetazolamide to Prevent Post Operative CSF Leak
Official title: Pilot Study of Acetazolamide to Prevent Post Operative Cerebrospinal Fluid (CSF) Leak in Patients Undergoing Endoscopic Skull Base Surgery
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants were identified per inclusion/exclusion criteria
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-01
Primary completion date: 2021-09-01
Completion date: 2021-09-01
Plan to share individual participant data: NO
Clinical trial NCT04657016: A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
Official title: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Acronym: SURMOUNT-3
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 579.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-29
Primary completion date: 2023-04-20
Completion date: 2023-05-12
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Plan Description:~Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: Access Criteria:~A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT02357849: Fluoxetine vs Aripiprazole Comparative Trial (FACT)
Official title: The Role of Antidepressants or Antipsychotics in Preventing Psychosis: Fluoxetine vs Aripiprazole Comparative Trial (FACT)
Acronym: FACT
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-07-31
Primary completion date: 2022-04-04
Completion date: 2022-04-04
Clinical trial NCT04344236: Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19
Official title: A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: This study was withdrawn by the institution to minimize risk to patients and staff with regard to COVID-19.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-04-09
Primary completion date: 2020-05-01
Completion date: 2020-05-09
Plan to share individual participant data: YES
IPD sharing description: The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: \[contact information for PI or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD access criteria: Requests should be directed to scott.rickert@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT04430933: A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
Official title: A Phase 1/2 Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor: NextCure, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-06
Primary completion date: 2022-06-30
Completion date: 2022-10-30
Plan to share individual participant data: NO
Clinical trial NCT04917055: iPACK Block With Dexamethasone For Total Knee Replacement
Official title: Impact of Adding iPACK Block With Dexamethasone to Existing APS Multimodal Analgesia Protocol for Patients Undergoing Total Knee Arthroplasty
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: staffing
Enrollment: 14.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-07
Primary completion date: 2022-06-07
Completion date: 2022-06-07
Plan to share individual participant data: NO
Clinical trial NCT05602961: A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
Official title: A Phase I/II Partially Randomized, Active-controlled Observer-blind, Dose-selection, Safety and Immunogenicity Study of GLB-COV2-043, an mRNA Vaccine Candidate Against SARS-CoV-2, Administered as a Single-vaccination Booster to Previously Vaccinated Adults
Sponsor: GreenLight Biosciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: to prioritize other programs.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-02-21
Primary completion date: 2024-09-30
Completion date: 2024-09-30